Neoplasm

Lore & Background

The word neoplasm is from Ancient Greek νέος- neo 'new' and πλάσμα plasma 'formation, creation'. Prior to the abnormal growth of tissue, cells often undergo metaplasia or dysplasia, though these do not always progress to neoplasia. Neoplasms can be benign, potentially malignant, or malignant. Benign tumors include uterine fibroids, osteophytes, and melanocytic nevi; they are circumscribed and do not transform into cancer. Potentially-malignant neoplasms include carcinoma in situ, which may transform into cancer over time. Malignant neoplasms, commonly called cancer, invade and destroy surrounding tissue, may form metastases, and are generally fatal if untreated.

Reader's Guide

Neoplasms are central to oncology, as malignant neoplasms (cancers) are a leading focus of medical research and treatment. The distinction between benign and malignant tumors guides clinical decisions: benign tumors are localized and non-life-threatening, while malignant tumors require aggressive intervention. The concept of clonality is critical for diagnosing lymphoid neoplasms, where demonstration of a single rearrangement of immunoglobulin or T cell receptor genes confirms neoplastic proliferation. DNA damage is considered the primary underlying cause of malignant neoplasms, with both hereditary and sporadic cancers linked to DNA repair deficiencies. The study of tumor growth using mathematics and continuum mechanics has revealed that active growth is often restricted to the outer edges and that stiffening of normal tissue can inhibit growth. Understanding neoplasms also involves recognizing that not all tumors are neoplastic—benign conditions like cysts, hematomas, and granulomas can present as masses without malignant potential.

Did You Know?

• The word neoplasm comes from Ancient Greek νέος- neo 'new' and πλάσμα plasma 'formation, creation'.
• Some neoplasms, such as leukemia and most forms of carcinoma in situ, do not form a tumor.
• A tumor is not synonymous with cancer; a tumor can be benign, precancerous, or malignant.
• DNA damage is considered the primary underlying cause of malignant neoplasms known as cancers.

Defining the Spectrum of Myeloproliferative Neoplasms

Myeloproliferative neoplasms represent a family of rare blood cancers in which the bone marrow overproduces red blood cells, white blood cells, or platelets beyond the body's needs. The name itself unpacks the pathology: "myelo" points to the marrow, "proliferative" captures the accelerated cell growth, and "neoplasm" signals that this growth is abnormal and uncontrolled. The World Health Organization and the International Consensus Classification jointly maintain the official taxonomy, and as of 2022 they recognize ten distinct entities, ranging from chronic myeloid leukemia and chronic neutrophilic leukemia to polycythemia vera, primary myelofibrosis (split into prefibrotic and overt fibrotic stages), essential thrombocythemia, juvenile myelomonocytic leukemia, chronic eosinophilic leukemia, and a residual category called MPN-NOS. A practical dividing line in clinical practice separates the BCR::ABL1-positive group, which essentially means CML, from all other MPNs. The three conditions most often grouped together as "classical MPNs" are essential thrombocythemia, polycythemia vera, and primary myelofibrosis.

Genetic Origins and the Decades-Long Latency Puzzle

At the cellular level, MPNs begin when precursor blast cells of the myeloid lineages acquire somatic mutations that drive uncontrolled proliferation. The most frequently implicated gene markers include JAK2, CALR, TET2, and MPL, and the specific mutation profile helps clinicians sort patients into the correct subtype. One of the most striking findings in MPN research is that at least some patients already harbor the mutated cell clone in utero, yet the median age at which disease manifests hovers around sixty-two years depending on the subtype. Why a single rogue clone can sit undetectable for decades remains an open question in hematology. Beyond genetics, MPNs share conceptual commonalities with chronic inflammatory diseases, and emerging evidence suggests that environmental exposures may act as additional triggers, much as they do in other long-standing inflammatory conditions. This layered etiology—genetic predisposition meeting possible environmental catalysts—helps explain why the disease landscape is so heterogeneous across patients.

Diagnosing Each Subtype: Markers, Thresholds, and Exclusions

A person with an MPN may be entirely asymptomatic when the condition is first caught on a routine blood panel, which is why the diagnostic workup varies considerably by suspected subtype. Depending on the clinical picture, physicians may order red cell mass determination, a bone marrow aspirate and trephine biopsy, arterial oxygen saturation and carboxyhaemoglobin measurements, neutrophil alkaline phosphatase levels, vitamin B12 or B12-binding capacity assays, serum urate tests, or direct DNA sequencing. Chronic myeloid leukemia is defined by the Philadelphia Chromosome, the BCR::ABL1 fusion. Chronic neutrophilic leukemia requires a CSF3R mutation plus exclusion of other neutrophilia causes. Essential thrombocythemia demands a platelet count above 450 × 10⁹/L, with JAK2 V617F present in up to fifty-five percent of cases and MPL mutations in up to five. Polycythemia vera is tied to JAK2 V617F in over ninety-five percent of patients, with the remainder carrying JAK2 exon 12 mutations, alongside elevated hemoglobin or hematocrit and characteristic marrow findings. The two myelofibrosis stages are distinguished by the degree of reticulin or collagen fibrosis seen on biopsy.

Treatment Realities, Prognosis Shifts, and Rising Incidence

No pharmaceutical cure currently exists for myeloproliferative neoplasms, and for most patients management centers on controlling symptoms and suppressing excessive blood-cell production with myelosuppressive agents. Hematopoietic stem cell transplantation offers a potential cure, but only for a small subset of patients. For essential thrombocythemia and polycythemia vera, the therapeutic priority is preventing thrombohemorrhagic complications, and low-dose aspirin has proven effective in both. In primary myelofibrosis, the goals shift toward alleviating anemia, splenomegaly, and other systemic symptoms. A landmark advance came with tyrosine kinase inhibitors such as imatinib, which lifted CML survival to near-normal life expectancy. More recently, the JAK2 inhibitor ruxolitinib gained approval for primary myelofibrosis, and trials of similar agents are underway for other MPN subtypes. Meanwhile, reported incidence rates are climbing—sometimes tripling—likely reflecting improved genetic diagnostics and refined WHO classification guidelines rather than a true surge in new cases, though wide geographic variation and suspected publication bias for essential thrombocythemia and primary myelofibrosis complicate the picture.

Gallery